UnitedHealth Group’s Optum Rx on June 23 said it will add two new Humira biosimilars, Boehringer Ingelheim’s Cyltezo and Sandoz’s Hyrimoz, to its standard formulary as of July 1. Optum Rx also includes Amgen’s Amjevita, which launched in January, on its formulary. The PBM — one of the “big three” and the first to cover any Humira biosimilar at parity — will also keep Humira in its formulary. Under the pharmacy benefit, Humira is a preferred product that requires utilization management, such as step therapy and/or prior authorization, for 93.5% of Optum Rx’s pharmacy lives.
SOURCE: MMIT Analytics, as of 6/26/23